Medivir's Licensee, Tango Therapeutics Dosed The First Patient With TNG348, A Novel USP1 Inhibitor
Portfolio Pulse from Benzinga Newsdesk
Medivir AB announced that its licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor for treating various HRD+ cancers. The FDA cleared the Investigational New Drug application for TNG348 in September 2023. TNG348 targets up to 50% of ovarian, 25% of breast, 10% of prostate, and 5% of pancreatic cancers with HRD+ including BRCA1/2 mutations. Tango is developing TNG348 based on a preclinical USP1 program licensed from Medivir in 2020.
January 04, 2024 | 7:59 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tango Therapeutics has begun dosing patients with TNG348, a drug licensed from Medivir, potentially impacting the treatment landscape for HRD+ cancers.
The dosing of the first patient with TNG348 by Tango Therapeutics is a significant milestone in the drug's development process, indicating progress in its clinical trials. This news is likely to be viewed positively by investors as it demonstrates advancement towards potential commercialization. Given that the drug targets a range of HRD+ cancers, which have a significant patient population, the successful development of TNG348 could lead to substantial market opportunities for Tango Therapeutics.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100